Angiotensin-converting enzyme inhibitor, angiotensin receptor blocker use, and mortality in patients with chronic kidney disease

Journal of the American College of Cardiology

Volumn 63, Issue 7, 2014, Pages 650-658

  Molnar, Miklos Z ^a,b   Kalantar Zadeh, Kamyar ^a   Lott, Evan H ^c   Lu, Jun Ling ^d   Malakauskas, Sandra M ^e,f   Ma, Jennie Z ^f   Quarles, Darryl L ^d   Kovesdy, Csaba P ^d,g  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY HEALTH NETWORK   (Canada)

^c Veterans Affairs Informatics and Computing Infrastructure   (United States)

^d UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

^g VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

angiotensin receptor blockers; angiotensin converting enzyme inhibitors; chronic kidney disease; mortality

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AFRICAN AMERICAN; AGED; ARTICLE; AS TREATED ANALYSIS; CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORTALITY; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; SYSTOLIC BLOOD PRESSURE; UNITED STATES; VETERAN; AGE DISTRIBUTION; COMORBIDITY; DRUG EXPOSURE; ETHNIC DIFFERENCE; OUTCOME ASSESSMENT; PROGNOSIS; RISK REDUCTION;

ANGIOTENSIN RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CHRONIC KIDNEY DISEASE; MORTALITY;

AGED; AGED, 80 AND OVER; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ANGIOTENSIN; RENAL INSUFFICIENCY, CHRONIC;

EID: 84896713380     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.10.050     Document Type: Article

References (52)

1. S.I. Hallan, J. Coresh, and B.C. Astor et al. International comparison of the relationship of chronic kidney disease prevalence and ESRD risk J Am Soc Nephrol 17 2006 2275 2284
2. US Renal Data System, USRDS 2011 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States 2011 National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases Bethesda, MD
3. P. Hatamizadeh, G.C. Fonarow, and M.J. Budoff et al. Cardiorenal syndrome: pathophysiology and potential targets for clinical management Nat Rev Nephrol 9 2013 99 111
4. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
5. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 316 1987 1429 1435
6. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, G. Dagenais for the Heart Outcomes Prevention Evaluation Study Investigators Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
7. M. Rahman, S. Pressel, and B.R. Davis et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Arch Intern Med 165 2005 936 946
8. E.J. Lewis, L.G. Hunsicker, R.P. Bain, R.D. Rohde for the Collaborative Study Group The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy N Engl J Med 329 1993 1456 1462
9. E.J. Lewis, L.G. Hunsicker, and W.R. Clarke et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
10. B.M. Brenner, M.E. Cooper, and D. de Zeeuw et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy N Engl J Med 345 2001 861 869
11. S.D. Solomon, M.M. Rice, and K. A Jablonski et al. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial Circulation 114 2006 26 31
12. I. Giatras, J. Lau, A.S. Levey for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials Ann Intern Med 127 1997 337 345
13. L.Y. Agodoa, L. Appel, and G.L. Bakris et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial JAMA 285 2001 2719 2728
14. A.K. Berger, S. Duval, and C. Manske et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure and chronic kidney disease Am Heart J 153 2007 1064 1073
15. A. Ahmed, T.E. Love, X. Sui, and M.W. Rich Effects of angiotensin-converting enzyme inhibitors in systolic heart failure patients with chronic kidney disease: a propensity score analysis J Card Fail 12 2006 499 506
16. E.M. Gibney, A.W. Casebeer, and L.M. Schooley et al. Cardiovascular medication use after coronary bypass surgery in patients with renal dysfunction: a national Veterans Administration study Kidney Int 68 2005 826 832
17. A. Ahmed, R.M. Centor, M.T. Weaver, and G.J. Perry A propensity score analysis of the impact of angiotensin-converting enzyme inhibitors on long-term survival of older adults with heart failure and perceived contraindications Am Heart J 149 2005 737 743
18. H. Reinecke, F. Matzkies, M. Fobker, G. Breithardt, and R.M. Schaefer Diabetic nephropathy, percutaneous coronary interventions, and blockade of the renin-angiotensin system Cardiology 104 2005 24 30
19. M.P. Tokmakova, H. Skali, and S. Kenchaiah et al. Chronic kidney disease, cardiovascular risk, and response to angiotensin-converting enzyme inhibition after myocardial infarction: the Survival And Ventricular Enlargement (SAVE) study Circulation 110 2004 3667 3673
20. W.Y. So, R. Ozaki, and N.N. Chan et al. Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients Hypertension 44 2004 294 299
21. F.A. McAlister, J. Ezekowitz, M. Tonelli, and P.W. Armstrong Renal insufficiency and heart failure: prognostic and therapeutic implications from a prospective cohort study Circulation 109 2004 1004 1009
22. J. Ezekowitz, F.A. McAlister, and K.H. Humphries et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with heart failure and coronary artery disease J Am Coll Cardiol 44 2004 1587 1592
23. P. Sharma, R.C. Blackburn, C.L. Parke, K. McCullough, A. Marks, and C. Black Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for adults with early (stage 1 to 3) non-diabetic chronic kidney disease Cochrane Database Syst Rev 2011 CD007751
24. G. Maschio, D. Alberti, G. Janin for the Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency N Engl J Med 334 1996 939 945
25. P. Ruggenenti, A. Perna, and G. Gherardi et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria Lancet 354 1999 359 364
26. F.F. Hou, X. Zhang, and G.H. Zhang et al. Efficacy and safety of benazepril for advanced chronic renal insufficiency N Engl J Med 354 2006 131 140
27. C.P. Kovesdy, E.H. Lott, and J.L. Lu et al. Hyponatremia, hypernatremia, and mortality in patients with chronic kidney disease with and without congestive heart failure Circulation 125 2012 677 684
28. C.P. Kovesdy, E.H. Lott, and J.L. Lu et al. Outcomes associated with microalbuminuria: effect modification by chronic kidney disease J Am Coll Cardiol 61 2013 1626 1633
29. A.S. Levey, L.A. Stevens, and C.H. Schmid et al. A new equation to estimate glomerular filtration rate Ann Intern Med 150 2009 604 612
30. National Kidney Foundation: K/DOQI guidelines. Definition and classification of stages of kidney disease Am J Kidney Dis 39 2002 S46 S64
31. VIReC Research User Guide: VHA Pharmacy Prescription Data, 2nd Edition 2008 US Department of Veterans Affairs, VA Information Resource Center (VIReC) Hines, IL
32. C.P. Kovesdy, and K. Kalantar-Zadeh Observational studies versus randomized controlled trials: avenues to causal inference in nephrology Adv Chronic Kidney Dis 19 2012 11 18
33. US Department of Veterans Affairs VA Information Resource Center Data Quality Update: Race 2009 U.S. Dept of Veterans Affairs VIRC Hines, IL
34. C.P. Kovesdy, A.J. Bleyer, and M.Z. Molnar et al. Blood pressure and mortality in U.S. veterans with chronic kidney disease: a cohort study Ann Intern Med 159 2013 233 242
35. VA Information Resource Center VIReC Research User Guide: VHA Medical SAS Outpatient Datasets FY 2006 2007 Health Services Research and Development Service, U.S. Department of Veterans Affairs Hines, IL
36. M. Rattanasompattikul, U. Feroze, and M.Z. Molnar et al. Charlson comorbidity score is a strong predictor of mortality in hemodialysis patients Int Urol Nephrol 44 2012 1813 1823
37. R.A. Deyo, D.C. Cherkin, and M.A. Ciol Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 45 1992 613 619
38. VIReC Research User Guide: Veterans Health Administration Decision Support System Clinical National Data Extracts 2nd edition 2009 US Department of Veterans Affairs HSRaDS, VA Information Resource Center Hines, IL
39. C.X. Pan, R.J. Glynn, H. Mogun, I. Choodnovskiy, and J. Avorn Definition of race and ethnicity in older people in Medicare and Medicaid J Am Geriatr Soc 47 1999 730 733
40. N. Arnold, M. Sohn, C. Maynard, and D.M. Hynes VIReC Technical Report 2: VA-NDI Mortality Data Merge Project 2006 VA Information Resource Center Hines, IL
41. R.B. D'Agostino Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265 2281
42. J.M. Robins Marginal structural models versus structural nested models as tools for causal inference E. Halloran, D. Berry, Statistical Models in Epidemiology: The Environment and Clinical Trials 1999 Springer-Verlag New York 95 134
43. J.E. Miller, M.Z. Molnar, and C.P. Kovesdy et al. Administered paricalcitol dose and survival in hemodialysis patients: a marginal structural model analysis Pharmacoepidemiol Drug Saf 21 2012 1232 1239
44. N. Pannu, and M.K. Nadim An overview of drug-induced acute kidney injury Crit Care Med 36 2008 S216 S223
45. M. Teng, M. Wolf, and M.N. Ofsthun et al. Activated injectable vitamin d and hemodialysis survival: a historical cohort study J Am Soc Nephrol 16 2005 1115 1125
46. P. Ruggenenti, I. Iliev, and G.M. Costa et al. Preventing left ventricular hypertrophy by ACE inhibition in hypertensive patients with type 2 diabetes: a prespecified analysis of the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Diabetes Care 31 2008 1629 1634
47. M.A. Konstam, M.W. Kronenberg, and M.F. Rousseau et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dilatation in patients with asymptomatic systolic dysfunction. SOLVD (Studies of Left Ventricular Dysfunction) Investigators Circulation 88 1993 2277 2283
48. M.G. Sutton, and N. Sharpe Left ventricular remodeling after myocardial infarction: pathophysiology and therapy Circulation 101 2000 2981 2988
49. S. Manabe, T. Okura, S. Watanabe, T. Fukuoka, and J. Higaki Effects of angiotensin II receptor blockade with valsartan on pro-inflammatory cytokines in patients with essential hypertension J Cardiovasc Pharmacol 46 2005 735 739
50. A.C. Peeters, M.G. Netea, B.J. Kullberg, T. Thien, and J.W. van der Meer The effect of renin-angiotensin system inhibitors on pro- and anti-inflammatory cytokine production Immunology 94 1998 376 379
51. R. Niimi, A. Nakamura, and Y. Yanagawa Suppression of endotoxin-induced renal tumor necrosis factor-alpha and interleukin-6 mRNA by renin-angiotensin system inhibitors Jpn J Pharmacol 88 2002 139 145
52. L.A. Stevens, C.H. Schmid, and T. Greene et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2 Am J Kidney Dis 56 2010 486 495